Checkpoint Therapeutics

Youtube Subscribe

Open: 2.89 Close: 2.65 Change: -0.24

Are you still looking for information about Checkpoint Therapeutics? An AI summarized it for you.

How much time have you spent trying to decide whether investing in Checkpoint Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Checkpoint Therapeutics are: …

Concept Map

Semantic Network

Stock Summary

Checkpoint Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company was incorporated in 2014 and is based in Waltham, Massachusetts..

Today's Summary

Checkpoint Therapeutics Inc has 14,943,570 shares outstanding. Wall Street analysts have said that the companys stock price is currently Undervalued. Checkpoint Therapeutics Inc (CKPT) stock is lower by -8.89% while the S&P 500 is lower. Checkpoint therapeutics inc (ckpt) stock has fallen -8.54% this week: buy, hold, or sell? Find out what this means to you and get the rest of the rankings on CKPT! Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) announced positive interim efficacy results from its registration-enabling trial of cosibelimab in patients with locally advanced cutaneous squamous cell carcinoma (cSCC) The objective response rate (ORR) in patients is 54.8%.

Today's News

Checkpoint Therapeutics Inc has 14,943,570 shares outstanding. Wall Street analysts have said that the companys stock price is currently Undervalued. Checkpoint Therapeutics Inc (CKPT) stock is lower by -8.89% while the S&P 500 is lower. Checkpoint therapeutics inc (ckpt) stock has fallen -8.54% this week: buy, hold, or sell? Find out what this means to you and get the rest of the rankings on CKPT! Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) announced positive interim efficacy results from its registration-enabling trial of cosibelimab in patients with locally advanced cutaneous squamous cell carcinoma (cSCC) The objective response rate (ORR) in patients is 54.8%.

Stock Profile

"Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc."

Keywords

Are looking for the most relevant information about Checkpoint Therapeutics? Investor spend a lot of time searching for information to make investment decisions in Checkpoint Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Checkpoint Therapeutics are: Checkpoint, Therapeutics, Inc, stock, CKPT, low, patient, and the most common words in the summary are: checkpoint, cancer, stock, therapeutic, aacr, research, report, . One of the sentences in the summary was: Checkpoint Therapeutics Inc has 14,943,570 shares outstanding. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #checkpoint #cancer #stock #therapeutic #aacr #research #report.

Read more →

Youtube Subscribe

---